Analysis of safety and efficacy of pegylated-interferon alpha-2a in hepatitis C virus positive hemodialysis patients: Results from a large, multicenter audit

Journal of Nephrology

Volumn 19, Issue 6, 2006, Pages 794-801

  Covic, Adrian ^a,b   Maftei, Irinel Doina ^a   Mardare, Nicoleta G I ^a   Ioniţǎ Radu, Florentina ^c   Totolici, Camelia ^d   Tuţǎ, Liliana ^e   Golea, Ovidiu ^b,d   Covic, Maria ^a   Volovǎţ, Carmen ^a   Gusbeth Tatomir, Paul ^a   Mircescu, Gabriel ^b,c  

^a C I PARHON NATIONAL INSTITUTE OF ENDOCRINOLOGY   (Romania)

^b The Romanian Renal Registry   (Romania)

^c CAROL DAVILA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^d Clinical Emergency County Hospital Pius Brinzeu Timisoara   (Romania)

^e Emergency County Hospital   (Romania)

Author keywords

Chronic hepatitis C infection; Efficacy; End stage renal disease; Hemodialysis; Pegylated interferon; Safety

Indexed keywords

PEGINTERFERON ALPHA2A; RECOMBINANT ERYTHROPOIETIN; VIRUS RNA;

ABDOMINAL PAIN; ADULT; ANEMIA; ANOREXIA; ARTICLE; ASTHENIA; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; DEPRESSION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EPISTAXIS; FEMALE; FLU LIKE SYNDROME; GINGIVA BLEEDING; HEMATOLOGIC DISEASE; HEMODIALYSIS; HEMODIALYSIS PATIENT; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INSOMNIA; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MENORRHAGIA AND METRORRHAGIA; MENTAL DISEASE; MONOTHERAPY; MULTICENTER STUDY; NEUTROPENIA; PANCYTOPENIA; PATIENT COMPLIANCE; SEPSIS; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT RESPONSE; VIRUS DETECTION; WEIGHT REDUCTION;

ADOLESCENT; ADULT; AGED; FEMALE; FOLLOW-UP STUDIES; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RENAL DIALYSIS; ROMANIA;

EID: 33947274748     PISSN: 11218428     EISSN: 17246059     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Jadoul M, Poignet JL, Geddes C, Locatelli F, Medin C, Krajewska M, Barril G, Scheuermann E, Sonkodi S, Goubau P. The changing epidemiology of hepatitis C virus (HCV) infection in hemodialysis: European multicentre study. Nephrol Dial Transplant 2004; 19: 904-9.
2. Fehr T, Ambuhl PM. Chronic hepatitis virus infections in patients on renal replacement therapy. Nephrol Dial Transplant 2004; 19: 1049-53.
3. Nakayama E, Akiha T, Marumo F, Sato C. Prognosis of anti-hepatitis C virus antibody-positive patients on regular hemodialysis therapy. J Am Soc Nephrol 2000; 11: 1896-902.
4. Pereira BJ, Natov SN, Bouthot BA Murthy BV, Ruthazer R, Schmid CH, Levey AS. Effects of hepatitis C infection and renal transplantation on survival in end-stage renal disease. The New England Organ Bank Hepatitis C Study Group. Kidney Int 1998; 53: 1374-81.
5. Kalantar-Zadeh K, McAllister CJ, Miller LG. Clinical characteristics and mortality in hepatitis C-positive hemodialysis patients: a population based study. Nephrol Dial Transplant 2005; 20: 1662-6.
6. Russo MW, Goldsweig CD, Iacobson IM, Brown RS. Interferon monotherapy for dialysis patients with chronic hepatitis C: an analysis of literature on efficacy and safety. Am J Gastroenterol 2003; 98: 1610-5.
7. Fabrizi F, Dulai G, Dixit V, Bunnapradist S, Martin P. Metaanalysis: interferon for treatment of chronic hepatitis C in dialysis patients. Aliment Pharmacol Ther 2003; 18: 1071-81.
8. Gish RG. Standards of treatment in chronic hepatitis C. Semin Liver Dis 1999; 19: 35-47.
9. Zeuzem S, Feinman SV, Rasenack J, Heathcote EJ, Lai MY, Gane E, O'Grady J, Reichen J, Diago M, Lin A, Hoffman J, Brunda MJ. Peginterferon Alpha-2a in patients with chronic hepatitis C. N Engl J Med 2000; 343: 1666-72.
10. Heathcote EJ, Shiffman ML, Cooksley WG, Dusheiko GM, Lee SS, Balart L, Reindollar R, Reddy RK, Wright TL, Lin A, Hoffman J, De Pamphilis J. Peg interferon alpha-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med 2000; 343: 1673-80.
11. Lindsay KL, Trepo C, Heintges T, Shiffman ML, Gordon SC, Hoefs JC, Schiff ER, Goodman ZD, Laughlin M, Yao R, Albrecht JK. A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology 2001; 34: 395-403.
12. Teta D, Luscher BL, Gonvers JJ, Francioli P, Phan O, Burnier M. Pegylated interferon for the treatment of hepatitis C virus in hemodialysis patients. Nephrol Dial Transplant 2005; 20: 991-3.
13. Kokoglu O, Ucmak H, Hosoglu S, Cetinkaya A, Kantarceken B, Buyukbese MA, Isik IO. Efficacy and tolerability of pegylated-interferon alpha-2a in hemodialysis patients with chronic hepatitis C. J Gastroenterol Hepatol 2006; 21: 575-80.
14. Russo MW, Galib R, Sigal S, Joshi V. Randomized trial of pegylated interferon alpha-2b monotherapy in hemodialysis patients with chronic hepatitis C. Nephrol Dial Tansplant 2006; 21: 437-43.
15. Ursea N, Mircescu G, Verzan C, Dima Z, Verzan M, Covic A, Mihaila V, Badulescu M. Chronic haemodialysis patients perception of health: early experiences in developing and outcomes assessment program. Nefrologia 2000; 5: 153-63.
16. Mahmoud IM, Sobh MA, El-Habashi AF, Sally ST, El-Baz M, El-Sawy E, Ghoneim MA. Interferon therapy in hemodialysis patients with chronic hepatitis C: study of tolerance, efficacy and post-transplantation course. Nephron Clin Pract 2005; 100: 133-9.
17. Cruzado JM, Casanovas-Taltavull T, Torras J, Baliellas C, Gil-Vernet S, Grinyó JM. Pretransplant interferon prevents hepatitis C virus-associated glomerulonephritis in renal allografts by HCV-RNA clearance. Am J Transplant 2003; 3: 357-60.
18. Degos F, Pol S, Chaix ML, Laffitte V, Buffet C, Bernard PH, Degott C, Carnot F, Riffaud PC, Chevret S. The tolerance and efficacy of interferon- in hemodialysis patients with HCV infection: a multicenter prospective study. Nephol Dial Transplant 2001; 16: 1017-23.
19. Bruchfeld A, Stahle L, Andersson J, Schvarcz R. Ribavirin treatment in dialysis patients with chronic hepatitis C infection - a pilot study. J Viral Hepatitis 2001; 8: 287-92.
20. Mousa DH, Abdala AH, AL-Shoail G, Al-Sulaiman MH, Al-Hawas FA, Al-Khader AA. Alpha-interferon with ribavirin in the treatment of hemodialysis patients with hepatitis C. Transplant Proc 2004; 36: 1831-4.
21. Martin P, Mitra S, Farrington K, Martin NE, Modi MW. Pegylated (40 kDa) interferon alpha 2a (Pegasys) is unaffected by renal impairment [abstract]. Hepatology 2000; 32 (Part 2): 842.
22. Lamb MW, Marks IM, Modi MW, Preston RA, Rappas SC. Peginterferon alpha-2a (40kDa) (PEGASYS) can be administered safely in patients with end-stage renal disease [abstract]. Hepatology 2001; 34: 326.
23. Zeuzem S, Welsch C, Herrmann E. Pharmacokinetics of Peginterferons. Semin Liver Dis 2003; 23: 23-28.
24. Bruchfeld A, Lindahl K, Reichard O, Carlsson T, Schvarcz R. Pegylated interferon and ribavirin treatment for hepatitis C in hemodialysis patients. J Viral Hepatitis 2006; 13: 316-21.
25. Russo MW. Pegylated interferon and ribavirin in hemodialysis patients [reply letter]. Nephol Dial Transplant 2006; 21: 1445-6.
26. Mircescu G, Capsa D, Covic M, Caprioara MG, Gluhovschi G, Golea O, Ursea N, Garneata L, Cepoi V, Constantinovici N, Covic A. Nephrology and renal replacement therapy in Romania: transition still continues (Cinderella story revisited). Nephrol Dial Transplant 2004; 19: 2971-80.